| OTTAWA HEART INSTITUTE RESEARCH CORPORATION Patent applications |
| Patent application number | Title | Published |
|---|
| 20110124568 | USE OF HEAT-SHOCK PROTEIN 27 FOR CARDIOVASCULAR DISEASE PREVENTION AND TREATMENT - A method of reducing cholesterol in a subject is provided. The method may be used to decrease serum cholesterol and/or arterial wall cholesterol. The method comprises administering a therapeutically effective amount of heat shock protein 27 (HSP27), or a co-factor, variant or analogue thereof. The method may be used to treat, prevent or reverse cardiovascular disease (including atherosclerosis); to decrease atherosclerotic lesion formation or rupture; to decrease apoptosis within a plaque; to decrease macrophage accumulation; and/or to reverse the accumulation of atherosclerotic plaque mass in a subject. Kits and pharmaceutical compositions comprising HSP27 for preventing or treating of cardiovascular disease, such as atherosclerosis, are also provided. | 05-26-2011 |
| 20090117090 | INHIBITION OF GLYCOGEN SYNTHASE KINASE 3 BETA IN ARTERIAL REPAIR AND STENT RE-ENDOTHELIALIZATION - A device having a kinase inhibitor for treating or preventing vascular disease in a subject and a method of treating a subject therewith, is disclosed. The device can be a stent coated with the kinase inhibitor. The kinase inhibitor can be a glycogen synthase kinase (GSK) inhibitor, such as a GSK-3β inhibitor. Coronary artery disease and ischemic heart disease can be treated. | 05-07-2009 |
| 20090100534 | MUSCLE LAMIN A/C INTERACTING PROTEIN, GENE ENCODING SAME, AND USES THEREFOR - Peptide sequences of human and murine muscle lamin A/C interacting protein and nucleotide sequences encoding same and are provided. Uses of the muscle lamin A/C interacting protein are also provided herein. | 04-16-2009 |
| 20090054340 | Use of heat-shock protein 27 for cardiovascular disease prevention and treatment - A method of preventing or treating cardiovascular disease is provided. The method comprises administering heat shock protein 27 (HSP27), a co-factor, variant or analogue thereof. The cardiovascular disease can include atherosclerosis. A pharmaceutical composition comprising HSP27 for use in the prevention or treatment of cardiovascular disease is also provided. | 02-26-2009 |
